Clene Inc.
NASDAQ:CLNN

Watchlist Manager
Clene Inc. Logo
Clene Inc.
NASDAQ:CLNN
Watchlist
Price: 6.68 USD 10.6%
Market Cap: 69m USD

Net Margin
Clene Inc.

-14 250.5%
Current
-8 018%
Average
-6.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-14 250.5%
=
Net Income
-30.5m
/
Revenue
214k

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Clene Inc.
NASDAQ:CLNN
68.3m USD
-14 250%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
400.9B USD
4%
US
Amgen Inc
NASDAQ:AMGN
176.1B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
31%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD
32%
AU
CSL Ltd
ASX:CSL
85.6B AUD
19%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
1%
NL
argenx SE
XBRU:ARGX
44.8B EUR
43%
No Stocks Found

Clene Inc.
Glance View

Market Cap
68.3m USD
Industry
Biotechnology

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 95 full-time employees. The company went IPO on 2018-08-27. The firm is focused on the treatment of neurodegenerative disease with potential first-in-class nanotherapeutics to treat energetic failure and neurological diseases. The Company’s lead drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals that drive critical cellular energetic metabolism in the central nervous system (CNS). CNM-Au8 increases energy production and utilization to accelerate neurorepair and improve neuroprotection. CNM-Au8 is being evaluated in a Phase III registration trial in amyotrophic lateral sclerosis (ALS) and a Phase II trial for the treatment of chronic optic neuropathy in patients with stable relapsing multiple sclerosis (MS). The firm has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses.

CLNN Intrinsic Value
HIDDEN
Show
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-14 250.5%
=
Net Income
-30.5m
/
Revenue
214k
What is the Net Margin of Clene Inc.?

Based on Clene Inc.'s most recent financial statements, the company has Net Margin of -14 250.5%.

Back to Top